Xcout Intel
Centivax
Centivax is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on accelerating the transition to a post-pathogen world by developing broad-spectrum vaccines, COVID-19 therapeutics, and antivenom antibodies.
Subscribe to see Centivax’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Centivax at a glance
Centivax is a biotechnology company headquartered in United States. It has raised at least $55M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $45M in July 2025. Xcout tracks 9 named people at Centivax, including Jacob Glanville (Chief Executive Officer).
Centivax leadership
- Jacob GlanvilleChief Executive Officer
- David TsaoChief Operating Officer
- Nicholas BaylessChief Technology Officer
- Gus ZeinerChief Innovation Officer
- Jerald SadoffChief Medical Officer
- Sawsan YoussefChief Science Officer
3 more named people on record for Centivax, with roles, board committees and tenure — see the full roster →
Centivax funding rounds
At least $55M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $45M | 6 named | |
| — | $10M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Centivax competitors
A few of Centivax's closest competitors — see the full list of competitors and alternatives →
Antiva Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm focuses on biotechnology research and developing treatments for viral infections and precancerous conditions.
IgGenix is a clinical-stage, venture-backed biotechnology company founded in 2019 and headquartered in South San Francisco, California. The company leverages its proprietary antibody discovery platform with a primary mission to cure allergies and other immunological diseases.
Tizona Therapeutics, Inc. is a privately held immunology company founded in 2015 and headquartered in South San Francisco, California. The company focuses on harnessing the power of the immune system to develop treatments.
C3J Therapeutics, Inc. is a clinical-stage biotechnology company based in Los Angeles, California, focused on improving human health through the development of targeted antimicrobials.
MalarVx, Inc. is a clinical-stage biopharmaceutical vaccine company located in Seattle, Washington, founded to develop innovative vaccines addressing global infectious diseases.
Excision BioTherapeutics Inc. is a San Francisco-based clinical-stage biotechnology company focused on developing advanced gene editing therapeutics to treat infectious diseases.
Get Centivax's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Centivax in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access